Exercise on GLP-1s: What the Evidence Actually Shows

Search “exercise on Ozempic” and you get two loud, opposite answers. One says the drug does everything and the gym is optional. The other says you will waste away into a weak, skinny version of yourself unless you lift five days a week.

Neither is what the research says. This page walks through what has actually been measured — in randomized trials, in pooled analyses, and in the trials that are still running — and is explicit about the places where nobody has data yet.

This is general information, not medical advice. Starting or changing an exercise program, particularly if you have heart disease, joint problems, diabetes or a history of falls, is a conversation with a healthcare provider.

About the label material on this page. Where this article describes dosing schedules, escalation, missed doses, storage or warnings, it is summarizing the FDA-approved prescribing information and Instructions for Use for Wegovy and Zepbound as published on DailyMed. Those documents are the authority, they are revised periodically, and they differ by product and by presentation (pen, prefilled syringe, single-dose vial, multi-dose vial). Follow the Instructions for Use that came with your own prescription, and take any question about your own dose, timing or supply to your prescriber or pharmacist rather than to this page.

Do you have to exercise for a GLP-1 to work?

No. And it is worth being honest about that, because a lot of fitness content quietly implies otherwise.

The STEP and SURMOUNT trials produced their headline results — roughly 15% mean weight loss on semaglutide 2.4 mg at 68 weeks, roughly 21% on tirzepatide 15 mg at 72 weeks — while giving participants relatively modest lifestyle instructions. In STEP 1, participants received a reduced-calorie diet of about 500 kcal/day below estimated need and counseling to reach 150 minutes a week of physical activity [1]. Nobody was supervised in a gym. Adherence to that activity advice was not the thing being tested.

So the drug does not require exercise to move the number on the scale. The question worth asking is a different one: what does exercise change about the result?

What does exercise actually change?

Three things, and they are separable.

1. What the weight is made of. Some of the weight lost on any weight-loss method is lean tissue, not fat. A 2026 systematic review and meta-analysis of 20 randomized trials and 15,782 participants put numbers on this. Lean mass made up 25% to 39% of total weight lost with incretin therapies — 35.2% with semaglutide, 25.4% with tirzepatide, 26.8% with liraglutide. Lifestyle intervention alone came in at 26.2%, which is to say: roughly the same range. The one condition that stood out was lifestyle plus resistance training, at 17.5% [2].

That last number is the single most useful figure in this whole topic. Note the important caveat, though: in that analysis, the resistance-training comparison came from lifestyle trials, not from trials that randomized people to lift weights while on semaglutide or tirzepatide. That trial does not exist yet in published form.

2. Function, not just composition. A 2026 meta-analysis in Drugs pooled 60 articles covering 1,250,717 individuals on GLP-1 drugs and musculoskeletal outcomes. It found no effect on bone outcomes, no significant change in joint-related measures, and reductions in lean body mass and fat-free mass — with the certainty of evidence rated low [3]. The authors’ conclusion is worth repeating: we do not yet know how clinically significant the muscle changes are. Grip strength, chair-stand time and walking speed are what would tell us, and they are measured far less often than DXA scans.

3. What happens when the drug stops. This is where exercise has the clearest evidence, and it is covered in its own section below.

How much lean mass are we actually talking about?

A 2026 network meta-analysis in the BMJ covering 262 trials and 99,791 participants ranked the drugs on both sides of the ledger. Tirzepatide reduced fat mass the most, by 25.7%, and also reduced lean mass the most, by 8.3% [4]. Subcutaneous semaglutide was the only drug in the analysis associated with reduced all-cause mortality.

The way to read that is not “tirzepatide is bad for muscle.” It is that bigger total weight loss brings bigger absolute losses of every tissue type, which is exactly what happens with diet, with surgery and with any other method. Proportion matters more than the raw number, and proportion is what training appears to shift.

One more framing point that is easy to lose: lean body mass is not the same thing as skeletal muscle. DXA-measured lean mass includes water, glycogen, organ tissue and connective tissue. Losing fluid and glycogen in the first weeks of a big calorie deficit registers as lean-mass loss on a scan without a single muscle fiber disappearing. MRI studies that isolate muscle volume generally report smaller proportions than DXA studies do.

Is there a trial of lifting weights on a GLP-1?

Not a completed, published randomized one — which is the most important sentence on this page.

What exists is:

• A registered trial in progress. LEAN-PREP, published as a protocol in BMJ Open in April 2026, is a 6-month single-center randomized controlled trial at the Dasman Diabetes Institute in Kuwait (NCT06885736), enrolling 232 adults on semaglutide or tirzepatide, randomized 1:1:1:1 to control, resistance exercise alone, protein supplementation alone, or both. The exercise arm is home-based, three sessions a week, progressing from one to three sets; the protein arm targets 1.6 g/kg/day. The primary outcome is quadriceps cross-sectional area measured by MRI [5]. That is the study the field is waiting for — and being single-center and 6 months, it will answer the mechanism question rather than the long-term one.
• A quasi-experimental program evaluation. A 2026 study in Diabetes, Obesity and Metabolism followed 245 adults in a 12-week virtual GLP-1 program with strength-focused physical activity coaching against usual care. The intervention group lost an adjusted mean of 6.0% of baseline body weight versus 3.3%, with greater fat loss (-3.3% vs -1.6%) and better muscle preservation (+0.6% vs +0.2%) [6]. Not randomized, and 12 weeks is short, but it is real-world and it points the same direction.
• A case series with a major confounder. A retrospective series of 93 men with obesity and testosterone deficiency combined tirzepatide, testosterone therapy, exercise and dietary counseling, and weekly behavioral support. Over 12 months they lost 20.9 to 22.6 kg of body weight and 16.6 to 17.1 kg of fat while gaining 1.6 to 3.7 kg of estimated skeletal muscle mass and 5.7 to 7.1 kg of grip strength [7]. Three caveats travel with those numbers and almost never travel with them online. Lean body mass still fell, by 4.0 to 6.1 kg — the muscle gain is the authors’ inference that non-muscle lean tissue fell faster than muscle. The muscle figure is bioelectrical-impedance-derived, not MRI or DXA. And the authors themselves write that the uncontrolled multimodal design precludes attributing the result to any individual component, testosterone included. Testosterone therapy is not an obesity treatment.
• A sober reality check. A 2026 narrative review of sarcopenia prevention during GLP-1 therapy states plainly that current evidence remains limited and that many recommendations are extrapolated from the general weight-loss, nutrition, exercise and sarcopenia literature rather than from GLP-1-specific trials [8].

So the honest summary: the mechanism is well established from decades of weight-loss research, the direction of the early GLP-1-specific data agrees, and the definitive trial has not reported.

What happens to results after you stop?

This is where exercise stops being a nice-to-have.

The S-LITE trial is the closest thing the field has to a clean answer. It randomized adults with obesity, after an initial low-calorie diet phase, to one of four arms for one year: placebo, liraglutide alone, supervised exercise alone, or exercise plus liraglutide. The combination arm produced roughly double the reduction in body-fat percentage of either single treatment and preserved lean mass [9].

Then everything stopped. In the post-treatment follow-up, the groups diverged sharply. The people who had been in the exercise arms — especially combination — held onto far more of what they had lost, and kept their activity levels up, than the people who had only taken the drug [10].

A 2026 narrative review in Healthcare specifically looked at structured exercise during and after incretin discontinuation and reached the same conclusion: controlled trial data show that exercise initiated during incretin treatment is associated with significantly less weight regain, greater sustained weight loss, and maintained physical activity levels one year after both the medication and the supervised program ended [11].

If you take one thing from this page: the training you do while on the drug is what you still have after it.

How much exercise, and what kind?

No GLP-1-specific prescription exists in any FDA label or major US society guideline. What reviews do is point back to the general adult baseline, then weight it toward strength.

The CDC / US Physical Activity Guidelines for Americans baseline for adults is 150 minutes a week of moderate-intensity aerobic activity, or 75 minutes of vigorous-intensity, or an equivalent mix — plus muscle-strengthening activity on at least 2 days a week covering all major muscle groups: legs, hips, back, abdomen, chest, shoulders and arms [12].

The GLP-1 nutrition and body-composition literature adds emphasis rather than new numbers:

• A 2025 American Journal of Clinical Nutrition review states that increased protein alone is likely inadequate to preserve muscle mass without structured resistance training, and that aerobic activity alone has a smaller effect on preserving lean mass [13]. Protein and training are a pair; neither works as well alone.
• A 2026 review of sarcopenia prevention recommends baseline assessment of body composition and muscle function, then individualized resistance and multicomponent exercise alongside adequate protein — with higher priority for older adults, people with low baseline muscle mass, sarcopenic obesity or chronic kidney disease [8].
• A 2025 perspective in Physical Therapy argues that physical therapists should expect to see GLP-1 users in practice and should account for medication side effects, reduced energy availability and lean-mass changes when programming [14].

What none of them do is tell an individual how many sets, at what load, on which days. That is programming, and it depends on your history, your joints and what you can actually sustain.

Will exercise make me lose faster?

Probably not dramatically, and that is the wrong reason to do it.

Appetite suppression is doing most of the work on the calorie side while you are on the drug. Adding exercise on top of a large pharmacological calorie deficit does not reliably accelerate scale weight — a point the S-LITE data supports, where the combination group’s advantage showed up most clearly in body composition and in the post-treatment phase rather than as a dramatically bigger number at one year.

There is also a performance myth worth retiring. A 2026 review of incretin-based therapies in sport found no consistent improvement in physical performance in humans and noted that these drugs are not on the World Anti-Doping Agency prohibited list [15]. Carrying less weight can make walking, stairs and daily tasks feel easier. That is a real and meaningful change. It is not the same as the drug improving your fitness.

Where the functional data is genuinely strong is in specific conditions. In heart failure with preserved ejection fraction, semaglutide improved six-minute walk distance and symptom scores in randomized trials — a physical-function benefit that shows up as something a person can feel. Across the drug class as a whole, though, the 2026 BMJ network meta-analysis found no drug convincingly improved quality-of-life scores beyond established minimal important differences [4].

What about energy, soreness and recovery?

Here the honest answer is that the evidence is thin and the reports are consistent.

Low energy during dose escalation is one of the most common things people describe, particularly in the first days after a dose increase. No trial has measured exercise capacity week by week through titration, so there is no published curve to point at. Clinical reviews attribute fatigue largely to inadequate total energy and protein intake rather than to a direct drug effect on muscle metabolism, which is consistent with the finding that a large share of GLP-1 users fall short of protein targets.

Two label-level safety points do apply to exercise specifically:

• Dehydration. Both the Wegovy and Zepbound labels warn that gastrointestinal adverse reactions can cause dehydration, which has led to acute kidney injury, sometimes requiring dialysis [16][17]. Exercising hard on a day when you cannot keep fluids down is exactly the wrong combination.
• Hypoglycemia. Both labels flag increased risk of low blood sugar when these drugs are used with insulin or an insulin secretagogue such as a sulfonylurea, and note that dose adjustment of those medications may be needed [16][17]. Exercise lowers blood glucose on its own. Anyone in that situation needs a prescriber-level plan, not internet advice.

Persistent fatigue, dizziness on standing, or a sharp drop in strength are reasons to contact a prescriber rather than to push through.

What should you measure?

If you only weigh yourself, exercise will look like it is doing nothing, because most of what it changes is invisible to a bathroom scale.

Things the literature actually uses, and that are easy enough to track at home:

• Grip strength — used across the sarcopenia literature, and the measure that moved in the tirzepatide case series [7].
• Chair-stand or sit-to-stand time — a standard lower-body function test.
• Walking distance or pace — the six-minute walk test is the trial version.
• Load and reps on a few reference lifts — the simplest progressive-overload signal there is.
• How clothes fit and waist measurement — waist circumference was a co-primary body-composition endpoint in SURMOUNT-5.

If strength and function are holding or improving while weight falls, the composition question is largely answering itself, whatever the DXA machine at the gym says.

The honest bottom line

1. Exercise is not required for the drug to produce weight loss. The trials proved that.
2. Exercise appears to change what the weight is made of. Lifestyle plus resistance training had the most favorable lean-mass profile in the 2026 meta-analysis, at 17.5% of weight lost versus 25-39% for drugs alone [2].
3. The definitive randomized trial of lifting on a GLP-1 has not reported. LEAN-PREP is running [5]. Anyone telling you the science is settled is ahead of the evidence.
4. The strongest exercise finding is about what comes after. Exercise started during treatment predicted less regain and maintained activity a year after everything stopped [10][11].
5. Protein and resistance training work as a pair. Neither substitutes for the other [13].
6. Baseline is 150 minutes of aerobic activity a week plus strength work on at least 2 days [12] — and what you can actually do every week beats what looks optimal on paper.
7. Clear the plan with a prescriber, especially around hydration, blood-sugar medication and any existing heart or joint condition.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine 2021;384:989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
2. Eisa N, Barood O. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes, Obesity and Metabolism 2026;28(6):4818-4827. https://doi.org/10.1111/dom.70666
3. Beaudart C et al. GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis. Drugs, September 2026. https://doi.org/10.1007/s40265-026-02365-3
4. Nong K et al. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ 2026;394:e372161. https://doi.org/10.1136/bmj-2026-372161
5. Alawadhi AA et al. LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial. BMJ Open 2026;16(4):e116911. https://doi.org/10.1136/bmjopen-2026-116911
6. Stanton LA et al. Quality Plus Quantity: Evaluation of a Virtual GLP-1 Programme With Physical Activity Support to Promote Healthy Body Composition Change During GLP-1 Weight Loss. Diabetes, Obesity and Metabolism, September 2026. https://doi.org/10.1111/dom.71152
7. Mendias CL, Awan TM. Increasing skeletal muscle mass and strength during incretin-based weight loss. Obesity Pillars 2026;19:100317. https://doi.org/10.1016/j.obpill.2026.100317
8. Belančić A et al. Preventive Strategies to Reduce Sarcopenia Risk During GLP-1-Based Anti-Obesity Therapy. Journal of Clinical Medicine 2026;15(15):5870. https://doi.org/10.3390/jcm15155870
9. Lundgren JR et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined (S-LITE). New England Journal of Medicine 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2028198
10. Jensen SBK et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. eClinicalMedicine 2024;69:102475. https://doi.org/10.1016/j.eclinm.2024.102475
11. Zeigler Z et al. Structured Exercise During and After Incretin-Based Pharmacotherapy Discontinuation: A Narrative Review of Mechanisms, Evidence, and Prescription Guidance. Healthcare 2026;14(15):2345. https://doi.org/10.3390/healthcare14152345
12. Centers for Disease Control and Prevention. Physical Activity Basics: Adults. https://www.cdc.gov/physical-activity-basics/guidelines/adults.html
13. Nutritional priorities to support GLP-1 therapy for obesity. American Journal of Clinical Nutrition 2025. https://ajcn.nutrition.org/article/S0002-9165(25)00240-0/fulltext
14. Mulcahy J, DeLaRosby A, Norwood T. Transforming Care: Implications of Glucagon Like Peptide-1 Receptor Agonists on Physical Therapist Practice. Physical Therapy 2025;105(6):pzaf061. https://pubmed.ncbi.nlm.nih.gov/40305684/
15. La Vignera S, Condorelli RA. Incretin-Based Therapies in Sports: Pharmacological Mechanisms, Performance-Enhancing Potential, and Anti-Doping Implications. International Journal of Molecular Sciences 2026;27(14):6116. https://doi.org/10.3390/ijms27146116
16. Wegovy (semaglutide) injection, prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
17. Zepbound (tirzepatide) injection, prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b